Skip to main content
Swiss GO Trial Group

Swiss-GO Glossary

The most important terms simply and briefly explained.

Glossar

Here you will find an alphabetical overview of the technical terms relating to clinical research in general. Click on the respective letter to get to your term of interest.

If you have any additional questions, please let us know: This email address is being protected from spambots. You need JavaScript enabled to view it.

Adjuvant therapy

Additional treatment after full surgical removal of a tumor in order to prevent a recurrence.

Adverse effects

Unwanted accompanying events that occur when a treatment is administered in the correct way.

Allogenic

From other people; e.g. allogenic bone marrow transplant.

Alopecia

Partial or total hair loss; possible side-effect after chemotherapy or radiation of the head region.

Ambulant

Just short stay in hospital without admission, as opposed to hospitalized.

Analgesic

Painkiller a drug inducing relief of pain without loss of consciousness.

Antiemetic

Drug to prevent the urge to vomit; often used to prevent vomiting in patient having chemotherapy.

Antibody

a protein present in blood that fights diseases by recognizing foreign substances present for example on bacteria.

Antigen

Substance that triggers the formation of antibodies.

Apoptosis

Cell death that is controlled and actively triggered (programmed) by cells. The inhibition of apoptosis genes can lead to uncontrolled cell division and probably plays a role in the development of cancer.

Benign

Not harmful. Benign tumors respect the natural tissue boundaries, unlike malignant tumors. They can become very large, but do not penetrate neighboring tissue and do not produce metastases.

Biopsy

A biopsy is a tissue sample taken from the body in order to examine it more closely.

Blinding

Procedure used to ensure that mental influences and expectations do not distort the outcome of a study. In a blinded study (single- or double-blind study), the study participants do not know which study group they are in, i.e. whether they are receiving a new treatment or a placebo.

Breast cancer

Cancer located in the breasts.

Cancer

Umbrella term to describe all malignant tumors or neoplasms including metastases. Benign tumors or cell clumps should not be referred to as cancer.

Carcinogenic

Substance that causes or promotes cancer.

Carcinoma

Malignant tumor that spreads from epithelial tissue, i.e. skin, mucous membrane or glandular tissue. Carcinomas are further differentiated according to the appearance and origin of the cells.

Carcinoma in situ

A tumor that is malignant in nature in terms of its cell composition but that is limited to a particular location, is not fast-growing, does not cross natural tissue boundaries and is not connected to the vascular system. It is a precursor stage of cancer.

Chemotherapy

A chemical substance that inhibits growth of tumor cells (cancer cells) in the body by interfering with cell division (cytostatics).

Chromosomes

Carriers of the genetic material in the cell nucleus; they contain the DNA chain molecule. Normal human body cells have 46 chromosomes, but the number and/or structure of chromosomes often varies in cancer cells.

Clinical study

Scientific investigations of people for people conducted according to strict medical and ethical rules. Their purpose is to obtain information in order to formulate better and more effective treatment recommendations.

Combination therapy

Therapy involving more than one drug or treatment method.

Compliance

The patient’s willingness to cooperate with diagnostic and therapeutic measures or to follow prescribed treatment.

Confounder

Risk factor that distorts the results of a study or conceals the actual cause.

Consolidation therapy

Second treatment after induction therapy for leukaemia with the aim of destroying remaining cancer cells by means of chemotherapy or radiotherapy.

Contraindication

Condition or situation which means that a particular treatment is not advisable.

Control group

Includes the study participants who are not receiving the new treatment but who, depending on the type of study, are receiving the standard treatment or standard procedure or a placebo.

Curative therapy

Treatment with the intention of curing the condition, in contrast to palliative therapy.

Cycle

Unit (of a treatment) that is repeated several times according to a schedule.

Cytological diagnosis

Microscopic examination of cells from smears, blood or tissue samples (biopsies) to detect pathological changes.

Cytostatic drugs

Non-endogenous substances that prevent the reproduction of tumour cells and often harm healthy cells in the process. Cytostatic drugs include both synthetic drugs and plant extracts.

Cytotoxic

Poisoning/damaging cells.

DNA

Desoxyribonucleic acid. Carrier of the genetic information of a living organism in the chromosomes in the cell nucleus.

Double-blind study

A study in which neither the patient nor the study doctor know which patient is receiving which active substance (or placebo).

Dysplasie

Fehlbildung, Abweichung der Gewebestruktur vom normalen Bild. Dysplasien können Krebsvorstufen sein.

Einfachblindstudie

Eine Studie, bei der die Patienten nicht wissen, welche Behandlung sie erhalten.

Endocrine

related to the hormone system.

Endpoint

Measurement point in a study to determine, for example, the occurrence of a disease, a symptom or a lab value.

Epidemiology

A record of the frequency of new conditions (incidence), deaths (mortality), causes and risk factors.

Erhaltungstherapie

Über eine längere Zeitperiode fortgeführte Chemotherapie, die den Erfolg der Induktionstherapie und Konsolidierungstherapie bei Krebs stabilisieren soll.

Erstlinientherapie

(auch Mittel der ersten Wahl) Wirkstoff oder Therapie, welche als am besten zur Behandlung einer bestimmten Erkrankung angesehen wird.

Erythrocytes

Red blood cells.

Ethics committees

High-level independent inspection bodies that assess the ethical and legal consequences of a study and ensure that study participants are protected.

First-line therapy

(sometimes called induction therapy, primary therapy, or front-line therapy) is the first therapy that will be tried.

Focal

Emerging from a focus of disease.

Gene

Hereditary factor, section of a molecule chain consisting of desoxyribonucleic acid (DNA). Genes are responsible for certain hereditary structures or functions of an organism.

Gene therapy

The insertion of genes into body cells to replace missing/altered genes in order to treat disease.

Good Clinical Practice

International guideline for the proper conduct of a clinical study.

Grading

The classification of tumours and tumour tissue according to their degree of differentiation. The figure (usually G1 to G3) describes how much the cancer cells differ from healthy, mature (differentiated) cells. This information is used to determine the malignancy of the tumour.

Hematological

Relating to blood or blood formation.

Histology

The science of the fine structure of body tissue.

Hormones

Chemical messenger substances formed in the body that reach their sites of action through the bloodstream. Hormones regulate growth, metabolism and reproduction, and can promote or reduce the growth of cancer cells.

Hyperplasia

Excessive, benign cell reproduction of tissue.

Immune system

The body’s defence system, protecting it against pathogens. It eliminates micro-organisms like viruses, bacteria and fungi, and plays a part in combating endogenous or other pathogenic cells that have become defective.

Immune therapy

Form of treatment in which cells or messenger substances of the endogenous defence system are used to bring about a defence reaction against tumour tissue.

Incidence

Frequency of new conditions, usually expressed per 100,000 residents per year.

Induction therapy

The first step in cancer treatment, using chemotherapy or radiotherapy to try to reduce the size of the tumour, or the cell count in the case of leukaemia.

Infiltrative

Invasive; in the case of tumours: spreading to surrounding tissue and destroying it.

Informed consent

The voluntary consent (usually in writing) or study participants after they have been informed about the purpose, conduct, expected benefits and risks and their rights and responsibilities.

Initial therapy

First treatment after diagnosis of an advanced tumour condition.

Interdisciplinary

Involving a number of different areas of specialisation.

Intergroup study

Large study conducted by several research groups on several thousand patients.

Kanzerogen

Krebsauslösend oder krebsbegünstigend; krebsauslösend oder krebsbegünstigender Stoff.

Karzinom

Bösartiger Tumor, der von Deckgeweben, d.h. Haut, Schleimhaut oder Drüsengewebe, ausgeht. Karzinome werden nach Erscheinungsbild der Zellen und ihrer Herkunft weiter unterschieden.

Klinische Studie

Wissenschaftliche Untersuchungen am Menschen für den Menschen nach strengen medizinischen und ethischen Regeln. Sie dienen der Klärung einer Fragestellung mit der Absicht, bessere und wirksamere Therapieempfehlungen zu formulieren.

Knochenmark

Im Knochenmark wird das Blut gebildet. Reife Blutzellen haben eine begrenzte Lebensdauer und müssen daher ständig im Knochenmark nachproduziert werden.

Kombinationstherapie

Therapie mit mehr als einem Medikament oder einer Behandlungsmethode.

Konsolidierungstherapie

Zweite Behandlung nach der Induktionstherapie mit dem Ziel, die restlichen Krebszellen bei Blutkrebs mit Chemo- oder Radiotherapie zu zerstören.

Kontraindikation

Bedingung oder Situation, die gegen die Durchführung einer Behandlungsmassnahme spricht.

Kontrollgruppe

Beinhaltet die Studienteilnehmenden, die nicht die neue Behandlung bekommen, sondern zum Vergleich die Standard-Behandlung bzw. je nach Studientyp das Standardvorgehen oder ein Placebo.

Krebs

Sammelbegriff für sämtliche bösartige Tumoren oder Neubildungen, die oftmals auch Metastasen bilden. Im engeren Sinne umfasst dies Karzinome und Sarkome, im Weiteren auch Leukämien und Lymphome. Gutartige Tumoren oder Wucherungen sind kein Krebs.

Kurative Therapie

Behandlung mit Heilungsabsicht; im Gegensatz zur palliativen Therapie.

Lesion

An impairment, change or injury to an organ or limb.

Leukaemia

Blood cancer; umbrella term for a type of cancer that occurs in the tissue that forms the blood (bone marrow). This is initially broken down into acute (rapidly progressing) and chronic (slowly progressing) forms of leukaemia. The division into myeloid or lymphatic leukaemias refers to the type of precursor cells that have become degenerate.

Leukocytes

White blood cells.

Local

In a specific area.

Lymphoma

Cancer of the lymphatic system (lymph gland cancer). There are many types of lymphoma, which can be divided into two groups: Hodgkin’s lymphoma (HL) (usually restricted to the lymph glands) and non-Hodgkin’s lymphoma (NHL) (can occur almost anywhere in the body).

Malignant

Harmful. In contrast to benign tumours, malignant tumours do not respect natural tissue boundaries but penetrate and destroy other tissue and can produce metastases in parts of the body far from their origin.

Metastases

Secondary tumours. These occur when cancer cells from the primary tumour are transported to other parts of the body via the bloodstream or lymphatic system. Metastases allow malignant tumours to be formed in other parts of the body.

Monoclonal antibodies

Proteins (immunoglobulins) that react with a single antigen. Researchers develop monoclonal antibodies that bond to specific antigens on the surface of the cancer cells in order to trigger an immune defence against these cells or to introduce a cancer-killing substance.

Monotherapy

Treatment with a single drug.

Morbidity

Likelihood of an individual developing a particular disease or condition.

Mortality

Proportion of deaths, normally expressed per 100,000 residents.

Multi-center study

Carried out at several hospitals (centres) at the same time.

Mutation

Change in the sequence of building blocks in the DNA genetic molecule. Mutations can lead to changes or losses in the function of genes, and so affect the behaviour of cells.

Neoadjuvant therapy

Pre-operative treatment (e.g. chemotherapy) carried out before surgery to remove a tumour. It is designed to reduce the size of the tumour and/or kill off tiny tumour cell clusters.

Neoplasm

Newly-formed abnormal cell growth, new formation, formation of new tissue, often malignant.

Oncogenes

Genes that are involved in the development of cancer. They are only carcinogenic if they have certain defects. Intact oncogenes have important regulatory functions in the cycle of cell division.

Oncology

The study of the development, diagnosis and treatment of cancers. In the modern understanding, this also involves the care, after-care, psychological support and rehabilitation of patients.

Open study

Both the doctor and the patient know the study group to which the participant belongs.

Oral

Via the mouth.

Overall survival

The length of time from either the date of diagnosis or the start of treatment for a disease that patients diagnosed with the disease are still alive.

Palliative

Treatment given to relieve the symptoms and reduce the suffering caused by cancer and other life-threatening diseases.

Palliative therapy

Treatment aimed at relieving symptoms or preventing complications in the case of incurable cancers, in contrast to curative therapy.

Pathogen

Causing disease, or a substance that does so.

Pathological

Related to disease.

Pathologist

Doctor who investigates and assesses pathological changes to body tissues and cells.

Patient information

Informs patients about the purpose, intention, effects and side effects of investigations and treatments. Written patient information is always provided to complement the information given by the doctor if the treatment is planned in the context of studies.

Percutaneous

Through the skin.

PET

Positron Emission Tomography. Computerised imaging procedure that produces images of cross-sections of bodily organs from which metabolic processes can be seen.

Pharmacodynamics

The study of the effects of drugs in the body, especially the profile of action, mechanism of action and the dose-effect relationship.

Pharmacokinetics

Description of the mechanism of action, i.e. the release, take-up, distribution, metabolisation and secretion of a particular drug.

Phase I study

First study in man; the search for new treatment methods that until this point have only been tested in the laboratory and in animal experiments.

Phase II study

Phase II studies investigate how effective and safe the new treatment is at the specified dose in combating a particular type of cancer.

Phase III study

The new treatment is compared to the usual method in order to find out whether the new treatment method is better.

Phase IV study

Rare side effects and interactions with other drugs are ascertained after the drug has been authorized for use.

Placebo

A dummy drug that does not contain any active substance.

Placebo effect

Effects and side effects caused by a dummy drug for which there is no pharmacological explanation. The placebo effect is based on positive expectations and mental effects.

Preclinical tests

Tests carried out in the laboratory and on animals to thoroughly investigate a newly developed drug before the clinical phase and before use in humans.

Prevalence

Frequency of a particular condition at a particular time in a defined group, usually the entire population

Primary tumor

The tumor which developed first; of which metastases originate.

Progression

The advance of the disease.

Proliferation

Reproduction of cells or tissue.

Radical resection

Surgical removal of tumor, in which the entire organ and if necessary large sections of surrounding tissue are removed in order to ensure that tiny tumor cell clusters nearby are also captured.

Radiochemotherapy

Combination of chemotherapy and radiotherapy (at the same time or consecutively).

Radiotherapy

The use of short-wave, very high-energy radiation, alone or in combination with other measures, to combat malignant tumours.

Randomization

A procedure followed in clinical studies, whereby participants are allocated at random to one or more treatment groups. The aim is to prevent the proven effect being subject to systematic bias.

Relapse

Recurrence, reappearance of a disease.

Remission

Decline of the disease. Complete or partial regression of the tumour, normally in response to treatment.

Resistance

Insensitivity to a treatment, e.g. of tumour cells to chemotherapy or of bacteria to antibiotics.

Sarcoma

Type of cancer starting in the bones, cartilage, fatty tissue, muscles or blood vessels.

Screening

Early detection of diseases before they become apparent through symptoms.

second-line therapy

Therapy that is applied when, after completion of the first treatment (first-line therapy), a therapeutic success fails, e.g. a tumour grows again or metastases form.

Significance

Importance; the difference between two treatments is significant if it is large enough that the study outcome cannot be due to chance.

Sponsor

A person, company, institution or organisation that is responsible for initiating, organising and/or funding the study.

Staging

The process of recording and classifying the local extent of the tumour, lymph node status and remote metastases (TNM classification) in order to find the most suitable treatment

Standard therapy

The conventional treatment whose efficacy has already been tried and proven. The best treatment available at the time.

Study arm

Patients are allocated to a study arm for a treatment that is to be investigated by comparison with another treatment. A study can include various study arms, e.g. an arm with a new treatment and an arm with standard treatment.

Subject

A healthy study participant.

Supportive therapy

Prevention and treatment of complications and side effects of cancer therapy.

Swissmedic

Swissmedic, which is part of the Swiss Federal Department of Home Affairs, is responsible for the quality, safety and efficacy of drugs and medicinal products, and registers, approves and monitors all clinical studies carried out with drugs that are not routinely prescribed.

therapy-resistant

not responding to a treatment/not treatable by the standard therapy.

third-line therapy

Therapy that is used when the effect of a second-line therapy diminishes or its therapeutic success fails, e.g. a relapse occurs or metastases form.

Toxicity, toxic

The poisonous effect of a substance, e.g. a cytostatic.

Trial doctor

The doctor leading and conducting a clinical study. He/she is highly qualified and already has experience with clinical studies.

Tumor

Swelling; in the strictest sense, a growth caused by the proliferation of cells that have escaped normal growth control; benign or malignant.

Tumour markers

Endogenous substances that enter the blood in higher concentrations when cancer is present. They are used mainly to monitor the course of known cancers: a rise in tumour marker concentration in the blood can be a sign of tumour growth. Markers can also be detected in other bodily fluids and tissue.

Verblindung

Vorgehen, um auszuschliessen, dass psychische Einflüsse und Erwartungen das Ergebnis einer Studie verfälschen. In einer verblindeten Studie (Blindstudie, Doppelblindstudie) wissen die Studienteilnehmenden nicht, welcher Studiengruppe sie angehören, d.h. ob sie eine neue oder eine herkömmliche Behandlung bzw. Placebo erhalten.

Zweitlinientherapie

Therapie, die angewendet wird, wenn nach Abschluss der ersten Behandlung (Erstlinientherapie) ein Therapieerfolg ausbleibt, z. B. ein Tumor wieder wächst oder sich Metastasen bilden.

Zyklus

Standardisiert ablaufende, mehrmals wiederholte Einheit (einer Behandlung).

Zytologische Diagnostik

Mikroskopische Untersuchung von Zellen aus Abstrichen, Blut oder Gewebeproben (Biopsien) auf krankhafte Veränderungen.

Zytostatika

Körperfremde Substanzen, die die Vermehrung von Tumorzellen verhindern und dabei oft auch gesunde Zellen schädigen. Zu den Zytostatika zählen sowohl synthetisch hergestellte Medikamente als auch Pflanzenextrakte.

Zytotoxisch

Zellgiftig, zellschädigend.

Address

Swiss GO Trial GroupGynecological OncologyHospital for WomenUniversity Hospital BaselSpitalstrasse 21CH-4031 BaselSwitzerland

Contact Info

Phone:  +41 61 265 75 00Fax: +41 61 265 93 22 E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Usefull links

SAKK-Die Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung ENGOT-The European Network for Gynaecological Oncological Trial groups
© Swiss GO. All rights reserved.
Powered by kallysoft AG
We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.